Tuberculosis Research Today is a free monthly online journal that collates and summarizes the latest research about Tuberculosis, including details on symptoms, causes, treatment, pulmonary, mycobacterium.

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant.

Senaratne RH, Mougous JD, Reader JR, Williams SJ, Zhang T, Bertozzi CR, Riley LW

School of Public Health, University of California, Berkeley, CA 94720, USA.

The emergence of drug-resistant Mycobacterium tuberculosis strains and the widespread occurrence of AIDS demand newer and more efficient control of tuberculosis. The protective efficacy of the current Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine is highly variable. Therefore, development of an effective new vaccine has gained momentum in recent years. Recently, several M. tuberculosis mutants were tested as potential vaccine candidates in the mouse model of tuberculosis. However, only some of these mutants were able to generate protection equivalent to that of BCG in mice. This study reports the vaccine potential of an attenuated 5'-adenosine phosphosulfate reductase mutant (DeltacysH) of M. tuberculosis. Immunization of mice with either BCG or DeltacysH followed by infection with the virulent M. tuberculosis Erdman strain demonstrated that DeltacysH can generate protection equivalent to that of the BCG vaccine.

Published 21 March 2007 in J Med Microbiol, 56: 454-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 Tuberculosis Research Today. All Rights Reserved.